Our Financial Institutions team has placed USD 2.2 billion in micro- & SME finance investments, through over 2,000 deals split between 28 funds/investors and 225 financial institutions in over 50 emerging economies.
Our Asset Management team manages 7 microfinance and SME impact funds, and one sustainable fund of fund, with USD 450 million of assets under management held by development banks, institutional and qualified private investors.
The information on this website has been approved by Symbiotics SA.
This website is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation
For Swiss residents, this website is directed exclusively to qualified investors (as defined in the Swiss Collective Investment Schemes Act of 23 June 2006 (the "CISA") and its implementing regulations) only and is not for distribution to retail customers, who should not rely on this material. The investment products referred to on the following pages have not been approved for public distribution in or from Switzerland by the Swiss Financial Market Supervisory Authority (FINMA). Accordingly, units of such Investment Products and information, documents or material pertaining to these Investment Products on the following pages may only be distributed in or from Switzerland to qualified investors.
The information and material are provided for information purposes only and are not to be used or considered to be an offer or solicitation to buy, sell or subscribe to any securities or other financial instruments.
Any information contained on this site does not constitute the investment policy of Symbiotics SA or an investment recommendation, but merely the different assumptions, views and analytical methods of the analysts who prepared it. Furthermore, the information, opinions and estimates expressed herein reflect a judgment as of its original publication date and are subject to change without notice.
The information and opinions presented by Symbiotics SA analysts have been obtained from sources believed to be reliable. Although all reasonable care was taken in gathering the information and formulating the opinions contained herein, Symbiotics SA does not make any representation whatsoever as to its accuracy or completeness. Accordingly, Symbiotics SA accepts no liability for any loss arising from the use of this site, which has been made available for information purposes only.
This information does not take into consideration the specific investment objectives, financial situation or particular needs of any person who may receive this report and invest in any investment product. Symbiotics SA has not taken any steps to ensure that any investments referred to are suitable for any particular investor. Any reports are not to be relied upon in substitution for the exercise of independent judgment. The value and income of any of the securities or financial instruments mentioned in this document can go up as well as down. The market value may be affected by changes in economic, financial or political factors, time to maturity, market conditions and volatility, or the credit quality of any issuer or reference issuer.
Furthermore, foreign currency rates may have a positive or adverse effect on the value, price or income of any security or related investment mentioned. Many factors may affect the value of a financial instrument, and accordingly, investors effectively assume all risks and may receive back less than they had originally invested. Any investors interested in buying a financial instrument should conduct their own investigation and analysis of the instrument as to the risks involved in transactions on such instrument. Past performance should not be taken as an indication or guarantee of future performance and no representation or warranty, expressed or implied, is made by Symbiotics SA regarding future performance.